TY - JOUR
T1 - Vasopressie-induced sensitization
T2 - involvement of neurohypophyseal peptide receptors
AU - Poulin, Paule
AU - Szot, Patricia
AU - Dorsa, Daniel M.
AU - Pittman, Quentin J.
PY - 1995/12/27
Y1 - 1995/12/27
N2 - Rats pretreated with an intracerebroventricular (i.c.v.) injection of 10 pmol of vasopressin or vasoprcssin analogs, including deamino-d-vasopressin, [pGlu1,Cyt6]vasopressin, [pGlu-Asn-Cys(Cys)]Pro-Leu-Gly-NH2, des-Gly-NH92-vasopressin, Pro-Leu-Gly-NH2, Pro-Arg-Gly-NH2, became markedly hyper-responsive to the motor effects, 24 h later, to a subsequent challenge dose of vasopressin, but not vasopressin-related peptides. A vasopressin V1 receptor antagonist, [d(CH2)15, Tyr(Me)2]vasopressin. but not the vasopressin V2 receptor antagonist, [d(CH2)15, Tyr(Et)2,Val4]vasopressin, or a more selective vasopressin V2 receptor antagonist, [d(CH2)15,d-Ile2,Ile4]vasopressin, or the oxytocin receptor antagonist, [d(CH2)15, Tyr(Me)2, Thr4,Orn8, Tyr-NH92]vasotocin ([d(CH2)15,Tyr(Me)2,Thr4,Tyr-NH92]OVT), blocked vasopressin and vasopressin analog-induced sensitization. Furthermore, both vasopressin V2 receptor antagonists were found to sensitize the brain to a subsequent vasopressin injection. This vasopressin V2 receptor antagonist-induced sensitization was also blocked by the vasopressin V1 receptor antagonist. Next. we wanted to determine if this sensitization process could involve the release of endogenous vasopressin in the brain as reflected in an amplification of vasopressin mRNA expression. However pretreatment of rats with an i.c.v. vasopressin injection was not associated with an increase in vasopressin mRNA expression in the bed nucleus of the stria terminalis, medial amygdala or the paraventricular nucleus of the hypothalamus when measured 0, 1, 3, 7, 12, or 24 h after the first vasopressin injection. As many vasopressin analogs can induce sensitization, we suggest that a novel type of receptor may be involved in the sensitization process.
AB - Rats pretreated with an intracerebroventricular (i.c.v.) injection of 10 pmol of vasopressin or vasoprcssin analogs, including deamino-d-vasopressin, [pGlu1,Cyt6]vasopressin, [pGlu-Asn-Cys(Cys)]Pro-Leu-Gly-NH2, des-Gly-NH92-vasopressin, Pro-Leu-Gly-NH2, Pro-Arg-Gly-NH2, became markedly hyper-responsive to the motor effects, 24 h later, to a subsequent challenge dose of vasopressin, but not vasopressin-related peptides. A vasopressin V1 receptor antagonist, [d(CH2)15, Tyr(Me)2]vasopressin. but not the vasopressin V2 receptor antagonist, [d(CH2)15, Tyr(Et)2,Val4]vasopressin, or a more selective vasopressin V2 receptor antagonist, [d(CH2)15,d-Ile2,Ile4]vasopressin, or the oxytocin receptor antagonist, [d(CH2)15, Tyr(Me)2, Thr4,Orn8, Tyr-NH92]vasotocin ([d(CH2)15,Tyr(Me)2,Thr4,Tyr-NH92]OVT), blocked vasopressin and vasopressin analog-induced sensitization. Furthermore, both vasopressin V2 receptor antagonists were found to sensitize the brain to a subsequent vasopressin injection. This vasopressin V2 receptor antagonist-induced sensitization was also blocked by the vasopressin V1 receptor antagonist. Next. we wanted to determine if this sensitization process could involve the release of endogenous vasopressin in the brain as reflected in an amplification of vasopressin mRNA expression. However pretreatment of rats with an i.c.v. vasopressin injection was not associated with an increase in vasopressin mRNA expression in the bed nucleus of the stria terminalis, medial amygdala or the paraventricular nucleus of the hypothalamus when measured 0, 1, 3, 7, 12, or 24 h after the first vasopressin injection. As many vasopressin analogs can induce sensitization, we suggest that a novel type of receptor may be involved in the sensitization process.
KW - Neuromodulation
KW - Oxytocin
KW - Structure-activity
UR - http://www.scopus.com/inward/record.url?scp=0029584576&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029584576&partnerID=8YFLogxK
U2 - 10.1016/0014-2999(95)00515-3
DO - 10.1016/0014-2999(95)00515-3
M3 - Article
C2 - 8788413
AN - SCOPUS:0029584576
SN - 0014-2999
VL - 294
SP - 29
EP - 39
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
IS - 1
ER -